PPBTNasdaqPharmaceutical PreparationsFiscal year ends December 31
PURPLE BIOTECH LTD.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 19, 2026
$1.08−0.06 (-5.26%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 40.0
- Dividend yield
- –
Purple Biotech statistics
Financials through Dec 31, 2025, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Purple Biotech | Industry median |
|---|---|---|
| Market Cap | $1.00M | $166.30M |
| Enterprise Value | -$7.77M | $88.19M |
| PE Ratio | 0.02 | 20.44 |
| PB Ratio | 0.10 | 2.03 |
| P/TBV Ratio | 0.43 | 2.29 |
Income (trailing twelve months)
| Measure | Purple Biotech | Industry median |
|---|---|---|
| Net Income | -$26.39M | -$22.46M |
| EPS (Diluted) | $0.03 | -$0.83 |
Returns
| Measure | Purple Biotech | Industry median |
|---|---|---|
| Return on Equity (ROE) | -124.0% | -53.2% |
| Return on Assets (ROA) | -96.6% | -40.9% |
Growth
| Measure | Purple Biotech | Industry median |
|---|---|---|
| EPS Growth (YoY) | -99.5% | -26.2% |
| EPS Growth (3Y CAGR) | -89.6% | -0.17% |
| EPS Growth (5Y CAGR) | -59.4% | 3.77% |
Balance sheet
| Measure | Purple Biotech | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $8.72M | $61.43M |
| Net Cash (Debt) | $8.72M | $15.35M |
| Net Cash Per Share | $0.00 | $0.66 |
| Equity (Book Value) | $9.71M | $49.09M |
| Book Value Per Share | $0.01 | $1.37 |
| Tangible Book Value | $2.35M | $23.52M |
| Working Capital | $2.11M | $76.81M |
Financial position
| Measure | Purple Biotech | Industry median |
|---|---|---|
| Current Ratio | 1.27 | 3.34 |
| Quick Ratio | 1.12 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Purple Biotech | Industry median |
|---|---|---|
| Operating Cash Flow | -$5.66M | -$12.35M |
| Capital Expenditures | -$3.00K | -$1.08M |
| Free Cash Flow | -$5.66M | -$20.22M |
| FCF Per Share | -$0.00 | -$0.42 |
Efficiency
| Measure | Purple Biotech | Industry median |
|---|---|---|
| Profits Per Employee | -$1.39M | -$703.34K |
| Employee Count | 19 | 74 |
Dividends and yields
| Measure | Purple Biotech | Industry median |
|---|---|---|
| Earnings Yield | -2628.6% | -23.3% |
| FCF Yield | -563.8% | -8.72% |
| Buyback Yield | -314.1% | -0.59% |
| Shareholder Yield | -314.1% | 0.00% |
Shares
| Measure | Purple Biotech | Industry median |
|---|---|---|
| Shares Outstanding | 1,858,910,000 | 58,127,000 |
| Shares Change (YoY) | -70.7% | 10.9% |
| Float | 1,817,930,000 | 49,136,700 |
| Shares Held by Insiders | 2.20% | 11.6% |
| Shares Held by Institutions | 0.00% | 59.4% |
Scores
| Measure | Purple Biotech | Industry median |
|---|---|---|
| Graham Number | $0.06 | $18.73 |
| Graham Upside | 10334.0% | -45.1% |
| Altman Z-Score | -13.41 | -0.22 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Purple Biotech's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.